Biotechnology

InterAx Biotech Announces Being the Recipient of a Highly Competitive European Grant to Fund Drug Development and Reports Financing Highlights

November 10, 2023 8:00 AM

InterAx Biotech AG, a pharmaceutical product development company pioneering computational pharmacology for drug discovery, announces being awarded a highly competitive and prestigious grant to apply its drug discovery and development platform to the breakthrough technology programs sponsored by the EU commission. ZURICH, SWITZERLAND / ACCESSWIRE / November 10, 2023 / The total volume of the Horizon Europe EIC Pathfinder project is EUR 3.7M,...

Read more

Invitation to MorphoSys' Third Quarter and First Nine Months 2023 Financial Results Conference Call on November 16, 2023

November 9, 2023 4:20 PM

Conference Call Alert PLANEGG and MUNICH, GERMANY / ACCESSWIRE / November 9, 2023 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) will publish its results for the third quarter and first nine months 2023 on November 15, 2023, at 10:00 pm CET (09:00 pm GMT; 04:00 pm EST). MorphoSys' Management team will host a conference call and webcast on November 16, 2023, at 02:00 pm CET (01:00 pm GMT; 08:00 am EST) to present the results for the third quarter and first...

Read more

Vibrant Wellness Launches the NutriProZ Longevity Program

November 9, 2023 9:30 AM

Pioneering Personalized Cellular Nutrition SANTA CLARA, CA / ACCESSWIRE / November 9, 2023 / Vibrant Wellness, a pioneer in research and lab diagnostics, announced the launch of the NutriProZ Longevity Program, offering healthcare professionals a personalized, data-driven strategy to optimize patient health and longevity. This program enables individualized cellular nutrition, moving away from generic supplements. A Data-Driven Strategy Rooted...

Read more

Lifeloc Reports Third Quarter 2023 Results

November 8, 2023 4:23 PM

WHEAT RIDGE, CO / ACCESSWIRE / November 8, 2023 / Lifeloc Technologies, Inc. (OTC PINK:LCTC), a global leader in the development and manufacturing of breath alcohol and drug testing devices, has announced financial results for the quarter ended September 30, 2023. Third Quarter Financial Highlights Lifeloc posted quarterly net revenue of $2.696 million in the third quarter of 2023, resulting in a quarterly net profit of $110 thousand, or $0.04...

Read more

Morphogenesis, Inc. Biomarker Analysis Data from IFx-Hu2.0 in Melanoma Refractory to Anti-PD1-Based Therapies Demonstrates Ability to Overcome Primary Resistance to Checkpoint Inhibitors and Trigger an Innate Immune Response

November 8, 2023 9:00 AM

IFx technology harnesses power of innate immune response leveraging body's natural first line of defense against foreign pathogens Production of tumor-specific antibodies recognizing hundreds of previously unrecognized melanoma tumor epitopes confirmed activation of a systemic immune response Data consistent with previously reported IFx-Hu2.0 data in advanced Merkel Cell Carcinoma (MCC) and Cutaneous Squamous Cell Carcinoma (cSCC) Data presented...

Read more

Blue Water Petroleum Corp (BWPC) To Showcase Hydrogen Fuel Processing Technology

November 8, 2023 9:00 AM

CHEYENNE, WY / ACCESSWIRE / November 8, 2023 / Blue Water Petroleum Corp's (OTC PINK:BWPC), wholly owned subsidiary Attimar SA, has developed cutting-edge hydrogen processing technologies which produce sustainable and ecologically viable fuels. These new H2 based fuels represent significant steps towards reducing the global dependency on fossil fuels, as they are designed to completely replace methane gas, which significantly reduces carbon...

Read more

Digital Utilities Ventures, Inc. (OTC:DUTV) Subsidiary and Nano Gas(TM) Environmental Agree to Exclusive Global License For Nanobubble Technology in Agriculture and Related Markets

November 8, 2023 9:00 AM

MANKATO, MN / ACCESSWIRE / November 8, 2023 / Digital Utilities Ventures, Inc. (OTC PINK:DUTV) announces that Nano Gas Environmental (Nano Gas™) has exclusively licensed the Nano Gas Technologies patents and intellectual property to the public company Digital Utilities Ventures, Inc. future subsidiary of Easy Modular Manufacturing (EMM) for use in the Global Agricultural and related markets (other than a few limited countries). EMM is...

Read more

Genflow Biosciences PLC Announces Appointment of Joint Broker

November 8, 2023 2:00 AM

LONDON, UK / ACCESSWIRE / November 8, 2023 / The Company (LSE:GNF)(OTCQB:GENFF), is pleased to announces today that it has appointed Capital Plus Partners Ltd to act as Joint Broker, alongside Clear Capital Markets, with immediate effect. The information communicated in this announcement is inside information for the purposes of Article 7 of Regulation 596/2014. For further information please contact: Genflow Biosciences Plc Dr Eric Leire Chief...

Read more

Orbit Technologies Inc. Raises $500k in Pre-Seed Round

November 7, 2023 10:30 AM

Dorm room startup Orbit Technologies Inc. raises $500k in oversubscribed pre-seed round to build immersive neurotechnologies for virtual reality. WASHINGTON, DC / ACCESSWIRE / November 7, 2023 / Orbit Technologies Inc. today announced a round of series pre-seed funding of $500,000 from gaming venture capital firm Dune Ventures. Orbit Raises $500k Pre-Seed Round Orbit co-founder & CEO Steven Pang at the Leonsis Family Entrepreneurship Prize...

Read more

AmplifyBio Selects Apprentice.io’s Tempo Manufacturing Execution System to Supercharge Manufacturing Capabilities as They Expand Capacity

November 7, 2023 7:00 AM

WEST JEFFERSON, OH / ACCESSWIRE / November 7, 2023 / AmplifyBio, a leading service provider in discovery, safety, and manufacturing services for the development of advanced therapies, has chosen Apprentice.io's cutting-edge Tempo Manufacturing Execution System (MES) to expand production capabilities and meet the increasing demand for modern modality commercialization on shorter de-risked timelines. Apprentice's, no-code, fully cloud-native MES...

Read more

BioMed X Launches a New Call for Application in Autoimmune Disease Research

November 7, 2023 6:00 AM

A new research team at the BioMed X Institute will develop a novel strategy to selectively target autoreactive plasma cells in autoimmune disease. HEIDELBERG, GERMANY / ACCESSWIRE / November 7, 2023 / BioMed X, an independent biomedical research institute, announced yesterday the launch of a Call for Application in immunology. This call aims to assemble a new research team to develop innovative strategies for neutralizing autoreactive plasma...

Read more

Tharimmune Executes Exclusive Global Licensing Agreement for Innovative Clinical Stage Asset for Chronic Pruritis

November 6, 2023 5:35 PM

Expects completion and topline data of a Phase 2 clinical trial in chronic pruritis over approximately 12 months after aligning with FDA on trial design Seeking first approval in an orphan disease, PBC, for the treatment of chronic pruritis in which more than 70% of patients suffer from debilitating symptoms BRIDGEWATER, NJ / ACCESSWIRE / November 6, 2023 / Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), a clinical-stage...

Read more

BioInvent Presents Positive Data at SITC from Clinical Phase 1/2a Trial of BI-1808 as Single Agent

November 3, 2023 12:10 PM

LUND, SE / ACCESSWIRE / November 3, 2023 / BioInvent International (STO:BINV): Preliminary data from Phase 1 part show encouraging early efficacy signals Robust partial response in one patient with gastrointestinal tumor; 7 cases of stable disease Favorable safety profile with no dose-limiting toxicity Further strengthens BioInvent pipeline with additional milestones expected 2023 BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV),...

Read more

African Ginger Patented for Influenza and SARS-CoV-2 Treatment: Insights from M2Bio Sciences Research Chair

November 3, 2023 9:45 AM

CAPE TOWN, SOUTH AFRICA / ACCESSWIRE / November 3, 2023 / Institute of Biomedical Research Corp. (OTC PINK:MRES), a vanguard entity at the forefront of nutraceutical biotechnology specializing in alternative plant-based cannabinoids, medical psilocybin, and cutting-edge mental health therapeutic research driven by artificial intelligence (AI), is pleased to provide the following update: The Annual Biomedical Research & Innovation Platform...

Read more

MorphoSys To Showcase Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2023 ASH Annual Meeting

November 2, 2023 9:45 AM

Following topline results expected in the coming weeks, the oral session at ASH 2023 in December will provide detailed findings from MANIFEST-2 Investor event focused on MANIFEST-2 with MorphoSys management and medical experts will be hosted onsite on Monday, December 11 Additional ASH 2023 presentations will highlight new findings from the Phase 2 MANIFEST study of pelabresib and clinical and preclinical studies of tafasitamab PLANEGG and...

Read more

GlobeStar Therapeutics Enters Into Definitive Agreement With Advanced Innovative Partners To Develop Clinical Studies and Strategies for Multiple Sclerosis Treatment

November 2, 2023 8:22 AM

RICHLAND, WA / ACCESSWIRE / November 2, 2023 / GlobeStar Therapeutics Corporation (OTC PINK:GSTC), (GSTC), a clinical-stage pharmaceutical company focused on advancing new therapies for Multiple Sclerosis (MS) and other neurological diseases today announced that building on its recent agreement with SMI HealthCare LLC (SMIHC) to manage an initial clinical trial, regulatory filings, intellectual property rights filings, manufacturing, sales and...

Read more

Lumira Ventures Portfolio Company enGene (Nasdaq:ENGN) Debuts as Publicly Traded Genetic Medicines Company

November 2, 2023 7:00 AM

CAD$191 million gross proceeds from the transaction to support the advancement of the clinical program and pipeline expansion Pivotal clinical trial for lead program EG-70 targeting BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) currently enrolling patients TORONTO, ON / ACCESSWIRE / November 2, 2023 / Lumira Ventures portfolio company enGene Holdings Inc., ("enGene" or the "Company"), a clinical-stage biotechnology company...

Read more

Stimlabs(R) LLC Granted Issuance of Two New Patents Further Establishing the Company’s Intellectual Property Position for Advancements in Regenerative Medicine

November 1, 2023 9:00 AM

ROSWELL, GA / ACCESSWIRE / November 1, 2023 / Stimlabs LLC, ("StimLabs"), a leader in regenerative medicine, continues to achieve advancements in the development and patenting of innovative, industry-leading technologies and products. The European Patent Office has granted StimLabs European Patent No. 3998089 relating to Compositions Derived from Placenta and Methods of Producing the Same. This comes on the heels of the U.S. Patent and...

Read more

Psycheceutical Bioscience Launches Wefunder Crowdfunding Campaign for Safer Psychedelic Dosing

November 1, 2023 8:00 AM

Investors are invited to support Psycheceutical's mission to revolutionize psychedelic medicines by taking part in the company's Wefunder Community Round. Community Crowdfunding Campaign now live for all levels of investors "Original Shark" Kevin Harrington, from the hit TV show Shark Tank, joined as an investor and strategic advisor Psycheceutical's NeuroDirect™ ketamine technology is the first ketamine topical being developed to treat PTSD...

Read more

BioMed X and AbbVie Start New Research Project in the USA

October 31, 2023 12:00 PM

BioMed X inaugurates its new institute in the USA with a research project on complex ex vivo models of tissue inflammation in collaboration with AbbVie. NEW HAVEN, CT / ACCESSWIRE / October 31, 2023 / BioMed X, an independent biomedical research institute, announces the start of a research project in collaboration with AbbVie to be hosted by the new BioMed X Institute in New Haven, CT, USA. The project aims to generate an organotypic human...

Read more